GRI-0621, an experimental oral therapy from GRI Bio, boosts lung function in adults with IPF, according to top-line clinical ...

Building on positive Phase 2 data, Puretech plans to launch a Phase 3 trial to further evaluate its experimental IPF therapy ...

Caring for someone you love is intimate, humbling, and grounding, writes columnist Ann Reynoso, who swapped caregiver roles with her husband.

Columnist Sam Kirton has wonderful memories of holiday presents, but the greatest gift he's received came in the form of a lung transplant.

[vc_row][vc_column][vc_column_text]Pulmonary fibrosis (PF) is a respiratory disease that causes the lung tissue to become thick and stiff. Over time, it turns into scar tissue, which is known as ...

Hello! My name is Kylene Henderson, and I’m excited to be writing a new column for Pulmonary Fibrosis News called “Life Beyond Limits.” In it, I hope to share some of the challenges our family has ...

Remembering loved ones who have passed invites waves of grief, but for columnist Sam Kirton, there is also joy to be found in the memories.

Taking oral dietary supplements of epigallocatechin-3-gallate (EGCG) — an antioxidant in green tea — may stop and reverse the pro-fibrotic (scarring) state of the lungs of people with idiopathic ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).

BMS-986020 is an anti-fibrotic drug being developed by Bristol-Myers Squibb, and is chemically a lysophosphatidic acid (LPA) receptor antagonist. The drug, an oral formulation, is in clinical trials ...